Roche: new data shows Ocrevus reduces multiple sclerosis
(CercleFinance.com) - Four years of treatment with Roche's Ocrevus showed a sustained reduction in disease activity in relapsing multiple sclerosis, new data presented at a congress has showed.
After four years of continuous treatment, the benefits of Ocrevus in reducing underlying disease activity were sustained, enabling patients to maintain low numbers of T1 gadolinium-enhancing (T1Gd+) lesions.
The new Ocrevus data was presented at the American Academy of Neurology (AAN) annual meeting in Los Angeles.
In a research note issued this morning, analysts at Barclays say Ocrevus is an "instrumental asset" for Roche in offsetting ongoing biosimilar pressures and estimate that the drug is worth 25 Swiss francs per share.
The Roche share is currently up 0.2% at 216.2 Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
After four years of continuous treatment, the benefits of Ocrevus in reducing underlying disease activity were sustained, enabling patients to maintain low numbers of T1 gadolinium-enhancing (T1Gd+) lesions.
The new Ocrevus data was presented at the American Academy of Neurology (AAN) annual meeting in Los Angeles.
In a research note issued this morning, analysts at Barclays say Ocrevus is an "instrumental asset" for Roche in offsetting ongoing biosimilar pressures and estimate that the drug is worth 25 Swiss francs per share.
The Roche share is currently up 0.2% at 216.2 Swiss francs.
Copyright (c) 2018 CercleFinance.com. All rights reserved.